TABLE 1
FROM:
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM
Hiroyuki Tagawa, Sivasundaram Karnan, Ritsuro Suzuki, Keitaro Matsuo, Xiaohua Zhang, Akinobu Ota, Yasuo Morishima, Shigeo Nakamura and Masao Seto
BACK TO ARTICLETable 1. Recurrent and most frequent regions of genomic gain and loss
| Gain/loss | Recurrent regions a | Most frequent regions b | ||||
|---|---|---|---|---|---|---|
| Chromosome c | Chromosome | Mega base d (Mb) | No. of cases (%) | Clone e | Gene f | |
| 3q13.11−q29 | 3q26.1 | 162.6−170.1 | 13−14 (45−48%) | RP11−576M8 | SERPINI2 | |
| (3q27.1) | 188.8 | 13 (45%) | RP11−211G3 | BCL6 | ||
| 6p21.32−p25.3 | 6p22.3−p25.3 | 0.4−24.6 | 5−7 (17−24%) | RP11−233K4 | IRF4 | |
| Gain | 7p14.3−p22.3 | 7p21.1−p21.3 | 8.7−19.8 | 9−10 (31−34%) | RP11−502P9 | HS7c218 |
| 8q13.2−q24.22 | 8q21.3−8q24.21 | 91.9−131.7 | 5−7 (17−24%) | RP1−80K22 | MYC | |
| 10p12.1−p12.2 | 10p12.1−p12.2 | 22.9−25.8 | 5−6 (17−21%) | RP11−301N24 | BMI-1 | |
| 17q23.2−q24.1 | 17q23.2−q24.1 | 58.8−66.1 | 5 (17%) | RP11−51F16 | — | |
| 1p36.23−p36.32 | 1p36.23−p36.32 | 2.5−7 | 8−9 (28−31%) | RP1−37J18 | — | |
| 1p11.2−p31.3 | 1p21.3−p22.1 | 95.4−101.2 | 14−15 (48−52%) | RP4−561L24 | GCLM | |
| 1q42.2−q43 | 1q42.2−q43 | 230.9−238.2 | 5 (17%) | RP11−781K5 | Q8WUH8 | |
| 2p11.2 | 2p11.2 | 89.4−89.9 | 19−24 (66−83%) | RP11−136K15 | KV1S(Igk) | |
| 2q13 | 2q13 | 108.7−111.9 | 5 (17%) | RP11−438K19 | BIM | |
| 5q21.1−q23.1 | 5q22.1−q22.3 | 104.8−114.5 | 5−6 (17−21%) | RP11−454E20 | — | |
| 6q16.2−q27 | 6q23.2−q24.1 | 133.3−146.5 | 10−11 (34−38%) | RP11−356I2 | TNFAIP3 | |
| 8p12−p23 | 8p23.1−p23.3 | 0.4−8.6 | 9−10 (31−34%) | RP11−240A17 | — | |
| Loss | 9p24.3−q31.1 | 9p24.2−p24.3 | 0.7−5.9 | 11−12 (38−41%) | RP11−130C19 | — |
| 9p21.3−p22.1 | 21.6−24 | 11−12 (38−41%) | RP11−149I2 | INK4a/ARF | ||
| 9q22.33−q31.1 | 92.5−95.5 | 12−13 (41−45%) | RP11−54O15 | C9orf3 | ||
| 10p12.31−p15.3 | 10p14−p15.3 | 2.2−18.7 | 8−9 (28−31%) | RP11−401F24 | C10orf47 | |
| 11q14.3−q23.2 | 11q22.3−q23.1 | 105−116.3 | 15−17 (52−59%) | RP11−758F15 | FDX | |
| (11q22.3) | 105−116.3 | 16 (55%) | RP11−241D13 | ATM | ||
| 13q13.2−q34 | 13q14.3−q21.1 | 46−50.8 | 15−16 (52−55%) | RP11−364I19 | RFP2 | |
| 13q34 | 99−112.5 | 13−15 (45−52%) | RP11−65D24 | bA65D24.2 | ||
| 15q13−q21.1 | 15q13.1 | 22.4−41 | 5−6 (17−21%) | RP11−125E1 | — | |
| 17p11.2−p13.3 | 17p13.3 | 0.8−6.6 | 13 (45%) | RP11−676J12 | NXN | |
| 17p13.1 | 6.6−18.8 | 8−9 (28−31%) | RP11−199F11 | SP53 | ||
| 19p13.2−p13.3 | 19p13.2 | 6.4−7.9 | 7−8 (24−28%) | RP11−42J18 | CD202 | |
| 22q12.1−q13.1 | 22q12.2 | 24.9−36.5 | 5−6 (17−21%) | RP1−76B20 | UCRX | |
Region of gain or loss was defined as the contiguity of at least three clones showing gain or loss, or, if not contiguous, clones showing a high copy number gain (log2 ratio >+1.0) or a homozygous loss (log2 ratio <-1.0).
a Recurrent region is defined as a region seen in 
5 of cases.
b The most frequent region of gain/loss was defined as the region with the highest frequency within each recurrent region.
c Regions are ordered according to their chromosomal position.
d According to Sanger Center Institute, February 2004 version.
e Representative of the most frequently gained or lost clone in each of the most frequent region. When the most frequently gained or lost clones share the same percentage of genomic aberrations in the most frequent regions, clones that include tumor-related genes are shown above those do not.
f Genes contained in the representative clone
